Horizon Pharma, which is launching DUEXIS for pain relief in rheumatoid arthritis/osteoarthritis patients, will see its quiet period end on Tuesday, September 6. On July 27, the company raised $50 million by offering 5.5 million shares at $9, below the range of...read more
In a week marked by the worst trading in months resulting from the political impasse on the debt ceiling, falling consumer sentiment, and GDP revisions, there was no ceiling on the stock prices for last week's consumer sector IPOs. The consumer sector deals...read more
Horizon Pharma, which is launching DUEXIS for pain relief in rheumatoid arthritis/osteoarthritis patients, raised $50 million by offering 5.5 million shares at $9, below the range of $10 to $12. Horizon Pharma plans to list on the NASDAQ under the symbol HZNP....read more
Horizon Pharma quiet period ends September 6
Horizon Pharma, which is launching DUEXIS for pain relief in rheumatoid arthritis/osteoarthritis patients, will see its quiet period end on Tuesday, September 6. On July 27, the company raised $50 million by offering 5.5 million shares at $9, below the range of...read more
Consumer IPOs defy bad economic data
In a week marked by the worst trading in months resulting from the political impasse on the debt ceiling, falling consumer sentiment, and GDP revisions, there was no ceiling on the stock prices for last week's consumer sector IPOs. The consumer sector deals...read more
Horizon Pharma prices IPO at $9, below the range
Horizon Pharma, which is launching DUEXIS for pain relief in rheumatoid arthritis/osteoarthritis patients, raised $50 million by offering 5.5 million shares at $9, below the range of $10 to $12. Horizon Pharma plans to list on the NASDAQ under the symbol HZNP....read more
Pre-IPO Research available on this week's eleven IPOs
Eleven IPOs are expected to price their offerings this week. Renaissance Capital will have ...read more